Drug Profile
Research programme: selective androgen receptor modulators - GlaxoSmithKline
Alternative Names: GSK-4336A; GSK-8698Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Oxazepines; Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA
- 31 Dec 2013 Preclinical development is ongoing
- 03 Sep 2007 Preclinical trials in Undefined indication in USA (unspecified route)